Academic literature on the topic 'Brij 35|sub'

Author: Grafiati

Published: 4 June 2021

Last updated: 11 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Brij 35|sub.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Brij 35|sub"

Rojas V., Heidel, Neyser Yóplac M., Carlos Millones Ch., Elena Torres M., and Ernestina Vásquez C. "Elaboración de licor de fruta de palmera pona (Ceroxylonperuvianum Galeano, Sanin & Mejía) proveniente del distrito de San Pablo de Valera, región Amazonas." APORTE SANTIAGUINO 5, no. 2 (December 19, 2012): 84. http://dx.doi.org/10.32911/as.2012.v5.n2.557.

Full text

Abstract:

La presente investigación consistió en la caracterización biométrica, fisicoquímica y elaboración de licor a partir de frutos macerados de palmera pona (Ceroxylonperuvianum). En la caracterización biométrica y fisicoquímica se empleó frutos en tres estados de madurez; en el proceso de maceración se empleó 200 y 400 g de frutos maduros macerados en aguardiente en tres grados alcohólicos: 50,45 y 40 °GL; la densidad, °Brix, % acidez total y pH de la maceración fueron analizados mediante un Diseño de Bloques Completamente al Azar (DBCA) con sub muestreo. La solución acuosa proveniente de la maceración se empleó para la elaboración del licor de pona ajustando los grados alcohólicos a 35 °GL y dulzor a 25 °Brix; evaluándose los atributos sensoriales de color y sabor mediante un DBCA con 12 panelistas semi enfrenados. La máxima extracción de la parte soluble de la fruta se obtuvo cuando se empleó 400 g de fruto en aguardiente 50 °GL y un tiempo de maceración de seis semanas; registrándose una densidad 0,979 g/cm3; acidez total 4,29%; °Brix 18,28 y pH 5,33. En la obtención de licor de fruta, el empleo de 400 g de frutos macerados con aguardiente a 40 °GL, permitió lograr la mayor preferencia en sabor por los panelistas con puntaje de 8,08 y de color 6,58, respectivamente

APA, Harvard, Vancouver, ISO, and other styles

Burke, Louise M., Rebecca Hall, Ida A. Heikura, Megan L. Ross, Nicolin Tee, Georgina L. Kent, Jamie Whitfield, et al. "Neither Beetroot Juice Supplementation nor Increased Carbohydrate Oxidation Enhance Economy of Prolonged Exercise in Elite Race Walkers." Nutrients 13, no. 8 (August 12, 2021): 2767. http://dx.doi.org/10.3390/nu13082767.

Full text

Abstract:

Given the importance of exercise economy to endurance performance, we implemented two strategies purported to reduce the oxygen cost of exercise within a 4 week training camp in 21 elite male race walkers. Fourteen athletes undertook a crossover investigation with beetroot juice (BRJ) or placebo (PLA) [2 d preload, 2 h pre-exercise + 35 min during exercise] during a 26 km race walking at speeds simulating competitive events. Separately, 19 athletes undertook a parallel group investigation of a multi-pronged strategy (MAX; n = 9) involving chronic (2 w high carbohydrate [CHO] diet + gut training) and acute (CHO loading + 90 g/h CHO during exercise) strategies to promote endogenous and exogenous CHO availability, compared with strategies reflecting lower ranges of current guidelines (CON; n = 10). There were no differences between BRJ and PLA trials for rates of CHO (p = 0.203) or fat (p = 0.818) oxidation or oxygen consumption (p = 0.090). Compared with CON, MAX was associated with higher rates of CHO oxidation during exercise, with increased exogenous CHO use (CON; peak = ~0.45 g/min; MAX: peak = ~1.45 g/min, p < 0.001). High rates of exogenous CHO use were achieved prior to gut training, without further improvement, suggesting that elite athletes already optimise intestinal CHO absorption via habitual practices. No differences in exercise economy were detected despite small differences in substrate use. Future studies should investigate the impact of these strategies on sub-elite athletes’ economy as well as the performance effects in elite groups.

APA, Harvard, Vancouver, ISO, and other styles

Amiarsi, Dwi. "Pengaruh Konsentrasi Oksigen dan Karbondioksida Dalam Kemasan Terhadap Daya Simpan Buah Mangga Gedong." Jurnal Hortikultura 22, no. 2 (August 1, 2013): 197. http://dx.doi.org/10.21082/jhort.v22n2.2012.p197-204.

Full text

Abstract:

ABSTRAK. Pengembangan buah di Indonesia termasuk yang di prioritaskan, namun kesegaran buah tidak dapat bertahan lama. Untuk memperpanjang ketahanan simpannya perlu diberi perlakuan dengan konsentrasi oksigen dan karbondioksida dalam kemasan. Penelitian dilaksanakan dari bulan Juni sampai bulan November 2007. Penelitian ini bertujuan untuk mendapatkan suhu penyimpanan dengan komposisi gas O2 dan CO2 yang tepat dalam pengemasan agar dapat mempertahankan mutu dan memperpanjang daya simpan buah mangga Gedong. Buah mangga dikemas dalam kantong plastik PE tebal 0,04 mm. Perlakuan komposisi gas yang dicoba terdiri dari 5,0% O2 + 5,0-5,8% CO2; 2,5% O2 + 5,0-5,8% CO2; 1,0% O2 + 5,0-5,8% CO2; Udara normal (21,0% O2 + 0,03% CO2), dan Udara terbuka serta suhu penyimpanan adalah 15oC dan 27-30oC. Penelitian disusun dengan Rancangan Acak Lengkap dalam pola Faktorial dengan tiga ulangan. Hasil penelitian menunjukkan bahwa kombinasi perlakuan konsentrasi gas 5,0% O2 + 5,0-5,8% CO2 pada penyimpanan suhu 15oC setelah 21 hari penyimpanan memberikan mutu terbaik dengan kandungan Padatan Total Terlarut 11,56oBrix, pH 4,09, vitamin C 29,44 mg/100g, dan kadar air 87,20% serta persentase busuk buah 13,47%. Penerapan teknik hasil penelitian ini dapat menguntungkan pengguna karena waktu untuk distribusi diperpanjang. ABSTRACT. The effect of gas composition of oxygen and carbon dioxide in the packages on Gedong mango fruit self life. In Indonesia the development of fruit is priority. The self life of mango fruits is short. For prolonging the self life of mango fruits necessary to three gas compositions of oxygen and carbon dioxide treatment followed in the packages. The experiment was conducted from June to November 2007. The aim of the study was to determine both of the proper initial gas composition (CO2:O2) at the best storage temperature for conservation and extention of storage life. The mango fruits were packed in polyethylene bags (0.04 mm) and various initial compositions of O2 and CO2 with two levels of storage temperature. The gas compositions were 5,0% O2 + 5,0-5,8% CO2; 2,5% O2 + 5,0-5,8% CO2; 1,0% O2 + 5,0-5,8% CO2; Normal air (21,0% O2 + 0,03% CO2), and Untreated, and the storage temperature at 15oC and 27-30oC. This experiments was arranged in factorial and Completely Randomized Design with three replications. The results showed that either application of initial gas concentration were 5,0% O2 + 5,0-5,8% CO2 at 15oC after 21 day storage was able to maintain the best quality mango fruit days with total soluble solid 11,56oBrix, pH 4,09, ascorbic acid content of 29,44 mg/100g, moisture content 87,20%, rotten 13,47%. Applying this resulting technique will benefit to user due to lengthen of the distribution time.

APA, Harvard, Vancouver, ISO, and other styles

Lynch, Ryan C., Victor A. Chow, David G. Maloney, Cameron J. Turtle, Stephen D. Smith, Mazyar Shadman, Chaitra S. Ujjani, et al. "Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas." Blood 134, Supplement_1 (November 13, 2019): 2889. http://dx.doi.org/10.1182/blood-2019-124962.

Full text

Abstract:

Introduction: CD19-specific chimeric antigen receptor (CAR) T-cell therapy is FDA approved in patients with relapsed or refractory large B-cell lymphomas. While 35-40% of patients may achieve a durable complete response (CR), the toxicity incurred with CAR-T therapy could impact the ability to receive subsequent treatment in those who progress after CAR-T infusion. Our prior data suggested that patients who experienced early progression had inferior overall survival. We now update our results and evaluate the impact of laboratory abnormalities and comorbidities at the time of progression on overall survival. Methods: Adults with large B-cell lymphomas who received CD19-specific CAR T-cells at the University of Washington/Seattle Cancer Care Alliance were included. Patients who received CAR T-cell therapy with additional concurrent protocol-specified therapy were excluded. Those who exhibited progressive disease (PD) or persistent lymphoma after CAR T-cell therapy were the focus of this study. We defined patients who progressed or received additional lymphoma directed therapy after last CAR-T cell infusion as early PD, with all other patients defined as late PD. We collected laboratory data closest to the date of progression. We defined an absolute neutrophil count < 1000, platelet count < 75K, Creatinine > upper limit of normal (ULN), INR > ULN, AST/ALT > 2.5x ULN, total bilirubin > ULN, and LDH > ULN as abnormal. Primary endpoint of this analysis was overall survival (OS) landmarked to date of progression. Secondary endpoints include sub-group analyses based on early PD as well as lab abnormalities at the time of progression. A multi-variate analysis with select baseline and progression variables was also performed. Results: We identified 66 patients who met the above criteria. Median follow up for the entire cohort is 30.4 months (range 0.1-64 months) by reverse KM method. Median time from last planned CAR infusion to progression was 43.5 days (range 11-658). Median OS of the entire cohort was 5.43 months (95% CI 3.75-12.2). 25 (38%) patients experienced early PD, which was associated with inferior OS (median 3.75 vs. 10.4 months, P=0.02). LDH > ULN at the time of progression defined a group with inferior outcomes (median OS 3.16 vs. 17.5 months, P<0.0001). Patients with at least one hematologic abnormality (ANC <1000 and/or platelets < 75K) had similar outcomes to those with higher values (median OS 4.18 vs 9.28 months, P=0.25). However, when we incorporated measurements of organ function, we found that patients with >1 indicator of hematologic and/or organ dysfunction (excluding LDH) at the time of progression had worse outcomes compared to those with one or fewer abnormalities (median OS 1.74 vs. 7.14 months, P=0.001). Multivariate analysis identified pre-CAR IPI score 4-5 (HR 6.33, 95% CI 1.97-20.36), LDH > ULN at progression (7.01, 95% CI 2.89-17.013), and abnormal creatinine at progression (5.32, 95% CI 1.71-16.53), as factors associated with increased risk of death. Conclusions: Patients with PD post CD19-specific CAR T-cell therapy, particularly those with early PD, elevated LDH, or renal failure experience extremely poor outcomes. These data can inform discussion of prognosis for patients who progress after CAR T-cell therapy and may predict which patients may benefit from additional anti-lymphoma therapy. Figure Disclosures Lynch: Johnson Graffe Keay Moniz & Wick LLP: Consultancy; Juno Therapeutics: Research Funding; Takeda Pharmaceuticals: Research Funding; T.G. Therapeutics: Research Funding; Incyte Corporation: Research Funding; Rhizen Pharmaceuticals S.A: Research Funding. Maloney:A2 Biotherapeutics: Honoraria, Other: Stock options ; Celgene,Kite Pharma: Honoraria, Research Funding; Juno Therapeutics: Honoraria, Patents & Royalties: patients pending , Research Funding; BioLine RX, Gilead,Genentech,Novartis: Honoraria. Turtle:Nektar Therapeutics: Other: Ad hoc advisory board member, Research Funding; Juno Therapeutics: Patents & Royalties: Co-inventor with staff from Juno Therapeutics; pending, Research Funding; Eureka Therapeutics: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Caribou Biosciences: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Novartis: Other: Ad hoc advisory board member; Precision Biosciences: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; T-CURX: Membership on an entity's Board of Directors or advisory committees; Allogene: Other: Ad hoc advisory board member; Kite/Gilead: Other: Ad hoc advisory board member; Humanigen: Other: Ad hoc advisory board member. Smith:Portola Pharmaceuticals: Research Funding; Pharmacyclics: Research Funding; Ignyta (spouse): Research Funding; Genentech: Research Funding; Denovo Biopharma: Research Funding; Ayala (spouse): Research Funding; Bristol-Myers Squibb (spouse): Research Funding; AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Research Funding; Acerta Pharma BV: Research Funding; Merck Sharp & Dohme Corp: Consultancy, Research Funding; Seattle Genetics: Research Funding; Incyte Corporation: Research Funding. Shadman:TG Therapeutic: Research Funding; Mustang Bio: Research Funding; Atara Biotherapeutics: Consultancy; Pharmacyclics: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; Sunesis: Research Funding; Verastem: Consultancy; Astra Zeneca: Consultancy; ADC Therapeutics: Consultancy; Sound Biologics: Consultancy; Celgene: Research Funding; Gilead: Consultancy, Research Funding; BeiGene: Research Funding; Acerta Pharma: Research Funding. Ujjani:Pharmacyclics: Honoraria; Atara: Consultancy; Gilead: Consultancy; Genentech: Honoraria; Astrazeneca: Consultancy; AbbVie: Honoraria, Research Funding; PCYC: Research Funding. Cassaday:Amgen: Consultancy, Research Funding; Pfizer: Consultancy, Honoraria, Research Funding; Incyte: Research Funding; Kite/Gilead: Research Funding; Merck: Research Funding; Seattle Genetics: Research Funding; Seattle Genetics: Other: Spouse's disclosure: employment, stock and other ownership interests. Till:Mustang Bio: Patents & Royalties, Research Funding. Shustov:Seattle Genetics, Inc.: Research Funding. Gopal:Seattle Genetics, Pfizer, Janssen, Gilead, Sanofi, Spectrum, Amgen, Aptevo, BRIM bio, Acerta, I-Mab-pharma, Takeda, Compliment, Asana Bio, and Incyte.: Consultancy; Seattle Genetics, Pfizer, Janssen, Gilead, Sanofi, Spectrum, Amgen, Aptevo, BRIM bio, Acerta, I-Mab-pharma, Takeda, Compliment, Asana Bio, and Incyte: Honoraria; Teva, Bristol-Myers Squibb, Merck, Takeda, Seattle Genetics, Pfizer, Janssen, Takeda, and Effector: Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

Cong Manh, Nguyen, Phan Van Minh, Nguyen Tri Quang Hung, Phan Thai Son, and Nguyen Minh Ky. "A Study to Assess the Effectiveness of Constructed Wetland Technology for Polluted Surface Water Treatment." VNU Journal of Science: Earth and Environmental Sciences 35, no. 2 (June 29, 2019). http://dx.doi.org/10.25073/2588-1094/vnuees.4372.

Full text

Abstract:

Abstract: The study aims to assess the applying effectiveness of constructed wetland technology for polluted surface water treatment. The experimental models were operated with 2 hydraulic loadings of 500mL/min/m2 (T1) and 1500mL/min/m2 (T2). The reed grass (Phragmites australis) was selected for the studying process. The surface water resource was removed from the pollutant components (TSS, BOD5, COD) and harmful microorganisms (fecal coliform) which aim to protect the water quality and aquatic ecosystems. The results showed the treatment effectiveness of loading of 500mL/min/m2 is higher than the loading of 1500mL/min/m2, especially in the reed planting trial. In particular, the treatment efficiency of pollutants such as TSS, BOD5, COD reached a high rate of 85%, 90%, and 87%, respectively. In addition, ANOVA statistical analysis showed the effectiveness of water quality parameters belong to two loadings were statistically significant (P<0.05). Thus, the surface water pollutant removal by subsurface vertical flow constructed wetland technology could be contributed to promoting the sustainable agricultural development. Keywords: Constructed wetland, removal, surface water, Phragmites australis, pollution. References: [1] Z. ElZein, A. Abdou, I.A. ElGawad, Constructed Wetlands as a Sustainable Wastewater Treatment Method in Communities, Procedia Environmental Sciences, 34 (2016) 605-617. https://doi.org/10. 1016/j.proenv.2016.04.053. [2] R.H. Kadlec, S.D. Wallace, Treatment Wetlands, CRC Press/Lewis Pucblishers, Boca Raton, FL, 2009.[3] J. Vymazal, Constructed Wetlands for Wastewater Treatment, Water, 2(3) (2010) 530-549. https://doi. org/10.3390/w2030530. [4] L. Volker, E. Elke, L.W. Martina, L. Andreas, M.G. Richard, Nutrient Removal Efficiency and Resource Economics of Vertical Flow and Horizontal Flow Constructed Wetlands, Ecological Engineering, 18(2) (2001) 157-171. https://doi.org/ 10.1016/S0925-8574(01)00075-1. [5] M. Ilda, F. Daniel, P. Enrico, F. Laura, M. Erika, Z. Gabriele, A cost-effectiveness analysis of seminatural wetlands and activated sludge wastewater-treatment systems, Environmental Management, 41(1) (2007) 118-129. https://doi.org /10.1007/s00267-007-9001-6. [6] J. Vymazal, The use of constructed wetlands with horizontal sub-surface flow for various types of wastewater, Ecological Engineering, 35 (2009) 1-17. https://doi.org/10.1016/j.ecoleng.2008.08.016. [7] S. Katarzyna, H.G. Magdalena, The use of constructed wetlands for the treatment of industrial wastewater, Journal of Water and Land Development, 34 (2017) 233–240. https://doi.org /10.1515/jwld-2017-0058. [8] S. Dallas, B. Scheffe, G. Ho, Reedbeds for greywater treatment-case study in Santa Elena-Monteverde, Costa Rica, Central America. Ecol. Eng. 23 (2004) 55-61. https://doi.org/10.1016/ j.ecoleng.2004.07.002. [9] Tổng cục Thống kê, Niên giám thống kê Việt Nam, NXB Thống kê, Hà Nội, 2018.[10] Bộ Tài nguyên và Môi trường, Báo cáo hiện trạng môi trường quốc gia – Môi trường nước mặt, Hà Nội, 2012.[11] UBND tỉnh Bình Dương, Quyết định số 3613/QĐ-UBND về việc Quy hoạch tài nguyên nước tỉnh Bình Dương giai đoạn 2016 - 2025, tầm nhìn đến năm 2035, Bình Dương, 2016.[12] M. Mirco, T. Attilio, Evapotranspiration from pilot-scale constructed wetlands planted with Phragmites australis in a Mediterranean environment, Journal of Environmental Science and Health, 48(5) (2013) 568-580. https://doi.org/ 10.1080/10934529.2013.730457. [13] K.J. Havens, H. Berquist, W.I. Priest, Common reed grass, Phragmites australis, expansion into constructed wetlands: Are we mortgaging our wetland future? Estuaries, 26 (2003) 417-422. https://doi.org/10.1007/BF02823718. [14] S. Aboubacar, R. Mohamed, A. Jamal, A. Omar, E. Samira, Exploitation of Phragmites australis (Reeds) in Filter Basins for the Treatment of Wastewater, Journal of Environmental Science and Technology, 11 (2018) 56-67. https://doi.org/10. 3923/jest.2018.56.67. [15] S.I. Abou-Elela, M.S. Hellal, Municipal wastewater treatment using vertical flow constructed wetlands planted with Canna, Phragmites and Cyprus, Ecol. Eng. 47 (2012) 209-213. https://doi.org/10.1016/j. ecoleng.2012.06.044.[16] H. Brix, A.C. Arias, The use of vertical flow constructed welands for on-site treatment of domestic wastewater: New Danish guidelines, Ecological Engineering, 25 (2005) 491-500. https://doi.org/10.1016/j.ecoleng.2005.07.009. [17] J. Puigagut, J. Villasenor, J.J. Salas, E. Becares, J. Garcia, Subsurface-flow constructed wetlands in Spain for the sanitation of small communities: A comparison study, Ecological Engineering, 30 (2007) 312-319. https://doi.org/10.1016/j.ecoleng. 2007.04.005. [18] R. Kadlec, R. Knight, Treatment Wetlands, CRC Press, 1996.[19] L. Yang, H.T. Chang, M.N.L. Huang, Nutrient removal in gravel-and soil-based wetlands microcosms with and without vegetation, Ecological Engineering, 18 (2001) 91-105. https://doi.org/10.1016/S0925-8574(01)00068-4. [20] D. Steer, L. Fraser, J. Boddy, B. Seibert, Efficiency of small constructed wetlands for subsurface treatment of single-family domestic effluent, Ecological Engineering, 18 (2002) 429-440. https://doi.org/10.1016/S0925-8574(01)00104-5. [21] J. Vymazal, The use of subsurface constructed wetlands for wastewater in Czech Republic: 10 years experience, Ecological Engineering, 18 (2002) 633-646. https://doi.org/10.1016/S0925-8574(02)00025-3. [22] C.S. Akratos, V.A. Tsihrintzis, Effect of temperature, HRT, vegetation and porous media on removal efficiency of pilot-scale horizontal subsurface flow constructed wetlands, Ecological Engineering, 29 (2007) 173-191. https://doi.org/ 10.1016/j.ecoleng.2006.06.013.

APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Brij 35|sub"

Bennis, Khalil. "Etude de l'adsorption et de la reduction electrochimique sur electrode de mercure de quelques cetones en presence de tensio-actifs en milieu aqueux." Clermont-Ferrand 2, 1988. http://www.theses.fr/1988CLF2E406.

Full text

Abstract:

Etude de la reduction electrochimique de l'acetophenone, l'oxyde de mesityle et l'ethylideneacetone en milieu aqueux en presence d'agents de surface anioniques (laurylsulfate de sodium), d'agents de surface cationiques (bromure de benzyltrimethylammonium et bromure de cetyltrimethylammonium) et d'agents de surface non ioniques (brij 35 et poly(oxyethylene))

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

Contents

Academic literature on the topic 'Brij 35|sub'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Journal articles on the topic "Brij 35|sub"

Dissertations / Theses on the topic "Brij 35|sub"